AstraZeneca Pharma India has reported results for first quarter ended June 30, 2012.
On standalone basis, the company has reported a net loss of Rs 8.14 crore for the quarter ended June 30, 2012 against net profit of Rs 16.74 crore for the corresponding period last fiscal. Total income decreased by 28.68% at Rs 99.12 crore during the quarter under review from Rs 138.98 crore in the year-ago period.
AstraZeneca operates through two entities, AstraZeneca Pharma India and AstraZeneca India in the country.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1863.30 |
| Dr. Reddys Lab | 1293.55 |
| Cipla | 1415.25 |
| Zydus Lifesciences | 1079.80 |
| Lupin | 2342.50 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: